$1.27
-0.22 (-14.53%)
Open$1.43
Previous Close$1.48
Day High$1.43
Day Low$1.26
52W High$3.72
52W Low$1.13
Volume—
Avg Volume2.11M
Market Cap86.76M
P/E Ratio—
EPS$-1.73
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,209.9% upside
Current
$1.27
$1.27
Target
$16.57
$16.57
$14.06
$16.57 avg
$23.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.33M | 18.18M | 17.68M |
| Net Income | -947,103 | -802,247 | -886,084 |
| Profit Margin | -4.9% | -4.4% | -5.0% |
| EBITDA | -1,287,077 | -1,124,832 | -1,061,399 |
| Free Cash Flow | -739,760 | -479,993 | -441,081 |
| Rev Growth | +21.0% | +13.7% | -3.4% |
| Debt/Equity | 0.36 | 0.44 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |